Initiatives to Strengthen FDA’s Generic Drug Review Process Include OGD Supplement and Peptide Teams

FDA’s Office of Generic Drugs (OGD) has created dedicated teams for the review of supplements and peptide drugs as part of an office-wide effort to improve the efficiency and effectiveness of its review processes and explore where policy and resource improvements are needed.

The supplement and peptide teams join other teams that OGD has created focused on Drug Master Files (DMFs) (IPQ “The News in Depth” August 30, 2012) and stability – also intended to streamline workflows and prepare for implementation of the Generic Drug User Fee Amendments (GDUFA).

A key driver for the OGD efforts is the expanded backlog of generics filings and the agreements reached through the user fee negotiations.  Additionally, workflows need to be examined with respect to which activities under GDUFA will require the applicant to pay fees and which will not.

At a CMC workshop co-sponsored by the Generic Pharmaceutical Association (GPhA) and FDA in late May in Bethesda, Maryland, OGD Acting Director and Office of Pharmaceutical Science (OPS) Deputy Director Keith Webber explained why the supplement review team was formed and what it is intended to accomplish.

He pointed out that the office receives changes in the form of CBE-30s, CBE-0s, and prior approval supplements, which the new team will manage “in a more organized fashion.”

Some of the CBEs “can be processed relatively quickly because they are less risky changes than prior approval supplements, which take more review and attention,” Webber noted.  The team will triage incoming change requests with regard to potential risk and time required for review and “manage the process better.”

[More on the OGD initiatives and how they meld with developments CDER-wide is provided for subscribers here.  Nonsubscribers can purchase the story for $195 by contacting Karen Bertani (  For subscription/license information, click here.]

See related stories:

Changes to OGD’s API DMF Process Target Submission Quality and Review Streamlining

The Role of QbD in ANDA Review Draws Comment from Generics Office Management

FDA’s Generics Office is Revising its QbR Questions to Sharpen Focus on QbD and Control Strategy

Raft of Comments on FDA Biosimilar Draft Guidances Draw Attention to Protein Definition, Interchangeability and Naming

Generic Injectable GMPs Again Prompt FDA Warning – APP Added to Non-compliance Watch List

FDA Release of Biosimilar Guidance Documents Opens Up New Chapter in Dialogue with Industry

FDA Generic Drugs Office Advances QbD, Review Processes and Quality Management System in Anticipation of User Fees